S-1: Phio Pharmaceuticals Files for Resale of Up to 5.9 Million Common Shares Following Recent Financings

Phio Pharmaceuticals is registering for resale up to 5.9 million shares of common stock, primarily related to warrants issued in recent private placements.

Summary

• Phio Pharmaceuticals has filed an S-1 registration statement to allow selling stockholders to resell up to 5,930,016 shares of common stock.
• These shares are issuable upon the exercise of warrants that were recently issued in a series of private placements.
• The warrants were issued in connection with registered direct offerings and concurrent private placements that occurred between December 19, 2024 and January 16, 2025.
• If all warrants are exercised for cash, Phio Pharmaceuticals would receive approximately $17.5 million in gross proceeds.
• The company will not receive any proceeds from the sale of the shares by the selling stockholders, except for the warrant exercise price.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol PHIO, with a last reported sale price of $2.77 per share on January 17, 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company has made progress in its clinical trials and has secured recent funding, it also faces significant risks and challenges, including the unproven nature of its technology, the early stage of its product candidates, and the need for substantial additional funding.

Positives

• The potential exercise of all warrants could provide Phio Pharmaceuticals with a significant cash infusion of approximately $17.5 million.
• The company has successfully raised capital through recent registered direct offerings and private placements.
• The company's lead drug candidate, PH-762, is currently in a Phase 1b clinical trial and has shown promising early results.
• The company has a proprietary INTASYL technology that is designed to make immune cells more effective in killing tumor cells.

Negatives

• The company will not receive any proceeds from the resale of shares by the selling stockholders.
• The company is dependent on the success of its INTASYL technology, which is unproven and may never lead to approved products.
• The company's product candidates are in early stages of development and may fail or experience delays.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or other issues.
• The company has a history of net losses and expects to continue to incur losses for the foreseeable future.
• The company's stock price has been and may continue to be volatile.

Risks

• The company is dependent on the success of its INTASYL technology, which is unproven and may never lead to approved and marketable products.
• The company's product candidates are in an early stage of development and may fail, experience significant delays, or not be successful.
• The company may experience delays or difficulties in identifying and enrolling patients in clinical trials.
• The company relies upon third parties for the manufacture of the clinical supply for its product candidates.
• The company will require substantial additional funds to complete its research and development activities.
• The company may not be able to maintain compliance with the continued listing requirements of The Nasdaq Capital Market.
• The price of the company's common stock has been and may continue to be volatile.
• The company is subject to significant competition and may not be able to compete successfully.
• The company is subject to potential liabilities from clinical testing and future product liability claims.
• The company is dependent on the patents it owns and the technologies it licenses, and if it fails to maintain its patents or lose the right to license such technologies, its ability to develop new products would be harmed.

Future Outlook

The company expects to continue to incur significant operating losses as it advances its product candidates through drug development and the regulatory process. The company anticipates that it will need to raise substantial amounts of money to fund a variety of future activities integral to the development of its business.

Industry Context

The biotechnology and pharmaceutical industries are intensely competitive, with many companies actively engaged in the discovery, development, and commercialization of products that may compete with Phio's product candidates. Many of Phio's competitors have substantially greater experience and greater research and development capabilities, staffing, financial, manufacturing, marketing, technical and other resources than Phio.

Comparison to Industry Standards

• The document does not provide specific details on comparable companies or projects.
• However, the document does mention that many of Phio's competitors have greater resources and experience.
• The document also notes that the biotechnology and pharmaceutical industries are intensely competitive.
• The document does not provide any specific benchmarks or industry standards for comparison.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution due to the potential exercise of warrants and future equity offerings.
• Employees may be affected by the company's financial performance and ability to secure additional funding.
• Customers (potential patients) may benefit from the development of new cancer treatments.
• Suppliers and creditors may be affected by the company's financial stability and ability to meet its obligations.

Next Steps

• The company expects to continue enrollment in its Phase 1b clinical trial for PH-762, with completion expected in the third quarter of 2025.
• The company will continue to assess its cash and cash equivalents and future funding requirements.
• The company will continue to develop its product candidates and seek marketing approval.

Key Dates

Keywords

Phio Pharmaceuticals, INTASYL technology, immuno-oncology, RNAi, PH-762, clinical trial, warrants, common stock, private placement, registered direct offering